| Trial ID: | L0173 |
| Source ID: | NCT05818995
|
| Associated Drug: |
Angiotensin Converting Enzyme Inhibitors, Angiotensin Ii Receptor Blockers, Dpp-4 Inhibitors, Glp-1 Receptor Agonists, Sglt2 Inhibitors, Calcium Channel Blockers, Β Receptor Blocker
|
| Title: |
Therapeutic Drug Use for CKD Patients
|
| Acronym: |
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Chronic Kidney Disease
|
| Interventions: |
DRUG: angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, calcium channel blockers, β Receptor blocker
|
| Outcome Measures: |
Primary: eGFR, The current treatment status and medication regimen of CKD patients with different risk stratification were analyzed by GFR staging., October , 2023|albuminuria, The current treatment status and medication regimen of CKD patients with different risk stratification were analyzed by albuminuria grading., October , 2023 |
|
| Sponsor/Collaborators: |
Sponsor: Qianfoshan Hospital
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
10000
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2022-07-01
|
| Completion Date: |
2024-06-30
|
| Results First Posted: |
|
| Last Update Posted: |
2024-04-03
|
| Locations: |
Xiao Li，MD, Jinan, Shandong, 250014, China
|
| URL: |
https://clinicaltrials.gov/show/NCT05818995
|
